Fredun Pharmaceuticals (539730) Q2 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half-year ended 30 September 2024, with statutory auditor's limited review yielding an unmodified conclusion.

Financial highlights

• Q2 FY25 revenue: ₹10,735.35 lakh, up from ₹8,198.51 lakh in Q2 FY24; H1 FY25 revenue: ₹18,616.43 lakh.

• Q2 FY25 net profit: ₹427.33 lakh, up from ₹393.62 lakh in Q2 FY24; H1 FY25 net profit: ₹840.32 lakh.

• Q2 FY25 EPS: ₹9.05, compared to ₹8.40 in Q2 FY24; H1 FY25 EPS: ₹17.80.

• Total expenses for Q2 FY25: ₹9,977.75 lakh, up from ₹7,621.65 lakh in Q2 FY24.

• No exceptional or prior period items reported in the quarter.

Key financial ratios and metrics

• Gross margin for Q2 FY25: 7.1% (profit before tax/revenue).

• Equity share capital as of 30 September 2024: ₹472.17 lakh; reserves: ₹12,614.90 lakh.

• Net cash outflow from operating activities for H1 FY25: ₹5,640.73 lakh, compared to inflow of ₹3,806.26 lakh in H1 FY24.

• Closing cash and bank balance as of 30 September 2024: ₹45.21 lakh.